ライフサイエンスコーパス: tumor-infiltrating lymphocyte

1 ociated with a dramatic increase of NKG2D(+)-tumor infiltrating lymphocytes.

2 s barriers to the metabolism and activity of tumor infiltrating lymphocytes.

3 rates, independent of increased pretreatment tumor infiltrating lymphocytes.

4 haracterized chief cells, oxyphil cells, and tumor-infiltrating lymphocytes.

5 tory cells and decreased abundance of CD8(+) tumor-infiltrating lymphocytes.

6 n association with elevated levels of Type-1 tumor-infiltrating lymphocytes.

7 or microenvironment that rapidly inactivates tumor-infiltrating lymphocytes.

8 ors in restricting TCR-mediated signaling in tumor-infiltrating lymphocytes.

9 H)2-skewed cytokine profile within blood and tumor-infiltrating lymphocytes.

10 Mechanisms were evaluated by analysis of tumor-infiltrating lymphocytes.

11 13 following adoptive transfer of autologous tumor-infiltrating lymphocytes.

12 carcinoma (RCC) tumors of the kidney and RCC tumor-infiltrating lymphocytes.

13 ated gene expression with protein status and tumor-infiltrating lymphocytes.

14 ls in the spleen and to generate E7-specific tumor-infiltrating lymphocytes.

15 8+ T cells and was associated with increased tumor-infiltrating lymphocytes.

16 n, especially tumor-induced angiogenesis and tumor-infiltrating lymphocytes.

17 fic CD8 responses detectable in PBMCs and in tumor-infiltrating lymphocytes.

18 tualized as resulting from reinvigoration of tumor-infiltrating lymphocytes.

19 mune cell scores and histologically detected tumor-infiltrating lymphocytes.

20 ith expression preceding the infiltration of tumor-infiltrating lymphocytes.

21 We find a higher response of patient-matched tumor infiltrating lymphocytes against antigens diferent

22 IHC was used to determine the presence of tumor infiltrating lymphocytes and antigen-presenting ce

23 lerated, inhibits RANK pathway and increases tumor infiltrating lymphocytes and CD8(+) T cells.

24 ing of freshly isolated CD8(+)/CD103(+) lung tumor-infiltrating lymphocytes and CD103(+) tumor-specif

25 ry CD8 T cells, as well as melanoma-reactive tumor-infiltrating lymphocytes and CD8 T cell clones.

26 sociated tumor cells increased the number of tumor-infiltrating lymphocytes and enhanced the survival

27 n of ex vivo-activated, melanoma Ag-specific tumor-infiltrating lymphocytes and high dose IL-2 result

28 137 mAbs and showed CD137 internalization in tumor-infiltrating lymphocytes and in activated human T

29 o ex vivo phenotypes of T and NK cells among tumor-infiltrating lymphocytes and in peripheral blood f

30 s corresponded with significant increases in tumor-infiltrating lymphocytes and increased expression

31 33 suggest its involvement in trafficking of tumor-infiltrating lymphocytes and indicate that STRL33

32 these DLBCLs include significant numbers of tumor-infiltrating lymphocytes and interdigitating dendr

33 umbers of morphologically distinct CD2+/CD3+ tumor-infiltrating lymphocytes and interdigitating S100+

34 In tumor-infiltrating lymphocytes and lymph node lymphocyte

35 ults suggest that IL-2 and -15 elaborated by tumor-infiltrating lymphocytes and macrophages may affec

36 condary endpoints included the generation of tumor-infiltrating lymphocytes and modulation of immune

37 e observed in the non-small cell lung cancer tumor-infiltrating lymphocytes and ovarian cancer tumor-

38 heckpoint inhibitors increases the number of tumor-infiltrating lymphocytes and overall survival afte

39 re, we detect neoepitope-specific T cells in tumor-infiltrating lymphocytes and peripheral blood from

40 nt exist based on the presence or absence of tumor-infiltrating lymphocytes and programmed death-liga

41 Stromal tumor-infiltrating lymphocytes and their association wit

42 and activity, attenuated Foxp3 expression in tumor-infiltrating lymphocytes, and decreased tumor burd

43 X40 on CD4(+) FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, and increased the antitu

44 ll type, presence of melanin, nuclear grade, tumor-infiltrating lymphocytes, and necrosis.

45 eg) that coexpress CD4 and CD25 in the PBLs, tumor-infiltrating lymphocytes, and regional lymph node

46 than 0, growth phase, thickness, ulceration, tumor-infiltrating lymphocytes, and sex were associated

47 zed that rapidly proliferating cancer cells, tumor-infiltrating lymphocytes, and vascular endothelial

48 eventing dendritic cell (DC)-mediated CD8(+) tumor-infiltrating lymphocyte apoptosis through regulati

49 Tumor-infiltrating lymphocytes appear to be a predictor

50 own that MHC class II (MHCII) expression and tumor infiltrating lymphocytes are important prognostic

51 Parathyroid tumor infiltrating lymphocytes are T cells by immunophen

52 Rationale Tumor infiltrating lymphocytes are widely associated wit

53 However, tumor-infiltrating lymphocytes are defective in effector

54 A paradox of tumor immunology is that tumor-infiltrating lymphocytes are dysfunctional in situ

55 In malignant melanoma, tumor-infiltrating lymphocytes are frequently reactive w

56 Tumor-infiltrating lymphocytes are key mediators of tumo

57 ound that the presence and quantification of tumor-infiltrating lymphocytes are significantly associa

58 gene product that was recognized by the bulk tumor-infiltrating lymphocytes as well as a dominant T c

59 the prognostic significance of intratumoral tumor infiltrating lymphocytes, as well as subsets of CD

60 The presence of tumor-infiltrating lymphocytes at diagnosis is reported

61 g Ag104, these cells made up the majority of tumor-infiltrating lymphocytes at the late stage of tumo

62 leukin (IL)-2-based therapy (five patients), tumor-infiltrating lymphocyte-based therapy plus IL-2 (n

63 Generation of tumor-infiltrating lymphocytes begins when tumor antigen

64 mor exhibit no gross defect in the number of tumor-infiltrating lymphocytes but have exaggerated angi

65 This correlated with decreased number of tumor-infiltrating lymphocytes but with elevated levels

66 Such T cells can be detected in tumor infiltrating lymphocytes, but whether such cells c

67 rity of melanoma patients analyzed and among tumor-infiltrating lymphocytes, but not in healthy donor

68 l expression in thousands of tumor cells and tumor-infiltrating lymphocytes can be used to obtain a s

69 ressor gene, Ki-67 proliferation marker, and tumor-infiltrating lymphocytes, carry prognostic signifi

70 0: 331-340, respectively, were recognized by tumor-infiltrating lymphocyte clone M37 in an HLA-A2-res

71 Tumor-infiltrating lymphocytes coexpressed PD-1 with the

72 ich were associated with increased levels of tumor-infiltrating lymphocytes compared with HPV-driven

73 NKG2D levels were augmented more in tumor-infiltrating lymphocytes compared with splenocytes

74 g lymphocytes in a subset of TNBCs with high tumor-infiltrating lymphocyte content.

75 imilar to those found in human melanoma, and tumor-infiltrating lymphocytes could be cultured from th

76 with RNA-seq, MHCII protein expression, and tumor-infiltrating lymphocyte counts.

77 s are currently testing strategies to infuse tumor-infiltrating lymphocytes, CTLs, Th cells, and Treg

78 ty for tumor antigens that were derived from tumor-infiltrating lymphocytes cultured for limited time

79 autologous tumor-reactive, rapidly expanded tumor infiltrating lymphocyte cultures and high-dose IL-

80 Finally, nonmelanoma-reactive tumor-infiltrating lymphocyte cultures developed antimel

81 In contrast, g9-209-reactive tumor-infiltrating lymphocyte cultures generally reacted

82 ere recorded and associated with presence of tumor infiltrating lymphocytes, cyclin E, adipophilin, p

83 Analysis of tumor-infiltrating lymphocytes demonstrated that CB T ce

84 ication of Tax+ tumor cells and nonmalignant tumor-infiltrating lymphocytes demonstrated that each of

85 tion, FACS-based enumeration of intracranial tumor-infiltrating lymphocytes directly correlated with

86 CD8(+) tumor-infiltrating lymphocytes displayed low expression

87 r immunity was accompanied by an increase of tumor-infiltrating lymphocytes displaying low PD-1 expre

88 Tumor-infiltrating lymphocyte estimated using immune cel

89 and induced type-1 polarization in CD8+CD28- tumor-infiltrating lymphocytes ex vivo.

90 phocyte fronts, whereas the majority of CD8+ tumor-infiltrating lymphocytes express high levels of PD

91 In the presence of Wnt5A-depleted MDSC, tumor-infiltrating lymphocytes expressed decreased PD-1

92 Treg in tumor-infiltrating lymphocytes expressed ICOS (mean fluo

93 We have further demonstrated that tumor-infiltrating lymphocytes expressed TIGIT and that

94 umor-specific CTL clone was established from tumor-infiltrating lymphocytes from a regressing pulmona

95 Analysis of tumor-infiltrating lymphocytes from Bach2-deficient mice

96 study, we show that engagement of CTLA-4 on tumor-infiltrating lymphocytes from low-dose melphalan (

97 termined on CD4+CD25high T cells in PBMC and tumor-infiltrating lymphocytes from melanoma patients (n

98 4(+) cells that are otherwise observed among tumor-infiltrating lymphocytes from mice treated with IL

99 biomarkers in circulating blood cells and in tumor-infiltrating lymphocytes from patients with resect

100 taneous T cell lymphoma and the isolation of tumor-infiltrating lymphocytes from primary squamous cel

101 from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes from stage I-IV HLA-A(*)0

102 Likewise, PD1 and CD137 were induced on tumor-infiltrating lymphocytes from surgically excised h

103 level in the resected tumor samples used for tumor-infiltrating lymphocyte generation.

104 CD8(+) tumor-infiltrating lymphocytes harboring ubiquitous TCRs

105 her T-cell receptor (TCR)-CD3 components, in tumor-infiltrating lymphocytes, human immunodeficiency v

106 fy gene signatures common to circulating and tumor infiltrating lymphocytes in the context of clear c

107 sed survival with the presence or absence of tumor-infiltrating lymphocytes in a given patient.

108 rong SFK_pY416 staining was also observed in tumor-infiltrating lymphocytes in a subset of TNBCs with

109 utility of this tool by using it to classify tumor-infiltrating lymphocytes in breast carcinoma and c

110 Patients with increased numbers of tumor-infiltrating lymphocytes in primary colon tumors a

111 Approaches to enhance tumor-infiltrating lymphocytes in the tumor bed may subs

112 hanges were correlated with Ki-67 and CD8(+) tumor-infiltrating lymphocytes in the tumor biopsies tak

113 urther validation of the clinical utility of tumor-infiltrating lymphocytes in this context is warran

114 ssociated with significantly lower levels of tumor-infiltrating lymphocytes in triple-negative breast

115 The presence of tumor-infiltrating lymphocytes in triple-negative breast

116 Recent clinical trials of ex vivo-expanded tumor-infiltrating lymphocytes indicated that differenti

117 nd inversely correlated with the presence of tumor infiltrating lymphocytes indicating that HS-27 flu

118 Systematic interrogation of tumor-infiltrating lymphocytes is key to the development

119 e log-fold increase in stimulation of a CD4+ tumor-infiltrating lymphocyte line.

120 ocking anti-CTLA-4 mAb) resulted in enhanced tumor-infiltrating lymphocyte-mediated anti-MOPC-315 cyt

121 al suppressive activity that may account for tumor-infiltrating lymphocyte-mediated immune evasion by

122 T-cell response against mutant KRAS G12D in tumor-infiltrating lymphocytes obtained from a patient w

123 gainst the transcription factor SOX10, using tumor-infiltrating lymphocytes obtained from a patient w

124 variation in a clinical setting, we screened tumor-infiltrating lymphocytes of an HLA-A*02:06 melanom

125 lls were present in the peripheral blood and tumor-infiltrating lymphocytes of lymphoma patients, cou

126 s also found in the draining lymph nodes and tumor-infiltrating lymphocytes of OSCC patients with ear

127 Moreover, CCR6(+) Treg cells isolated from tumor-infiltrating lymphocytes or draining lymph nodes m

128 ade relies on reinvigoration of pre-existing tumor-infiltrating lymphocytes or on recruitment of nove

129 le CD4(+) T-cell clones isolated either from tumor-infiltrating lymphocytes or peripheral blood monon

130 01) but not with cell type, mitotic figures, tumor-infiltrating lymphocytes, or PAS-positive patterns

131 munogenic response consistent with increased tumor infiltrating lymphocytes, particularly within meta

132 system resulting in more IFN-gamma-producing tumor-infiltrating lymphocytes per tumor when compared w

133 tor function on human memory CD8 T cells and tumor-infiltrating lymphocytes reactive against melanoma

134 CD8(+)tumor-infiltrating lymphocytes reactive to clonal neoant

135 Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an effective c

136 Examination of tumor-infiltrating lymphocytes revealed an elevated popu

137 We also mined a tumor-infiltrating lymphocyte sample from a patient with

138 ent in the in vitro-expanded and transferred tumor-infiltrating lymphocyte samples and certain T cell

139 alpha-beta paired T-cell receptors (TCRs) of tumor-infiltrating lymphocytes shared between multiple p

140 Tumor-infiltrating lymphocytes showed a prevalent inhibi

141 Expanded tumor-infiltrating lymphocytes showed TCR repertoire ske

142 his investigation, we explored the effect of tumor-infiltrating lymphocyte subpopulations on lung can

143 ave PD-L1 expression in both tumor cells and tumor-infiltrating lymphocytes, suggesting that immune c

144 Tumor-infiltrating lymphocytes that accomplish tumor rej

145 apy as evidenced by an active recruitment of tumor-infiltrating lymphocytes that are capable of lysin

146 -1:28 engineering reinstated Th1 function in tumor-infiltrating lymphocytes that had been functionall

147 ls of chemotherapy or radiation can increase tumor-infiltrating lymphocytes that overcome resistance

148 ly, irradiated mice had increased numbers of tumor-infiltrating lymphocytes that secreted IFN-gamma a

149 oximately 1.11x10(11) HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of fou

150 Melanoma prognosis is dictated by tumor-infiltrating lymphocytes, the migratory and functi

151 Twenty separate tumor infiltrating lymphocyte (TIL) bulk cultures and a

152 cells had corresponding effects on local DN tumor infiltrating lymphocyte (TIL) levels and inversely

153 ed stage melanoma patients undergoing either tumor infiltrating lymphocyte (TIL)-based or anti- progr

154 hin DNA; making them more prone to attack by tumor infiltrating lymphocytes (TIL) and macrophages.

155 ymphodepletion before infusion of autologous tumor infiltrating lymphocytes (TIL), objective response

156 ntigen tyrosinase was isolated from a CD4(+) tumor-infiltrating lymphocyte (TIL 1383I) and introduced

157 4 MART-1:27-35 (MART-1) melanoma Ag-reactive tumor-infiltrating lymphocyte (TIL) clones from the tumo

158 onstrated the role of CD103 integrin on lung tumor-infiltrating lymphocyte (TIL) clones in promoting

159 Reduction of CCL5 expression caused tumor-infiltrating lymphocyte (TIL) desertification, whe

160 h presence of mitoses (1.8 [1.0-3.3]), lower tumor-infiltrating lymphocyte (TIL) grade (nonbrisk, 0.5

161 a unique melanoma Ag recognized by a CD4(+) tumor-infiltrating lymphocyte (TIL) line.

162 mmune checkpoint, both of which can increase tumor-infiltrating lymphocyte (TIL) numbers.

163 Finally, studies conducted on tumor-infiltrating lymphocyte (TIL) samples that were ad

164 Finally, we evaluated the immune cell tumor-infiltrating lymphocyte (TIL) score for correlatio

165 analyzing the pattern of gene expression of tumor-infiltrating lymphocyte (TIL), which can minimize

166 checkpoint blockade and adoptive transfer of tumor-infiltrating lymphocyte (TIL)-based therapies.

167 is of the recognition of melanoma Ags by the tumor-infiltrating lymphocytes (TIL) 1790, isolated from

168 Direct competition between tumor-infiltrating lymphocytes (TIL) and cancer cells fo

169 We isolated tumor-infiltrating lymphocytes (TIL) and intra-hepatic l

170 A, and CD4 mRNAs and their relationship with tumor-infiltrating lymphocytes (TIL) and PD-L1 IHC expre

171 combined treatment exhibited an increase in tumor-infiltrating lymphocytes (TIL) and T cells, as rev

172 CD8(+) tumor-infiltrating lymphocytes (TIL) are defective in cy

173 e TCR repertoires of Tregs and Tconvs within tumor-infiltrating lymphocytes (TIL) are largely distinc

174 Tumor-infiltrating lymphocytes (TIL) are potent mediator

175 CD8+ tumor-infiltrating lymphocytes (TIL) are severely defici

176 Tumor-infiltrating lymphocytes (TIL) are well known to b

177 naturally occurring and genetically modified tumor-infiltrating lymphocytes (TIL) by inhibitory recep

178 Adoptive T-cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) can induce tumor re

179 ternatively, adoptive transfer of autologous tumor-infiltrating lymphocytes (TIL) can mediate tumor r

180 (+) T cells from melanoma patients' PBMC and tumor-infiltrating lymphocytes (TIL) capture melanoma Ag

181 Exhaustion of tumor-infiltrating lymphocytes (TIL) correlated with exp

182 Two thirds of CD8(+) tumor-infiltrating lymphocytes (TIL) expressed PD-1, whe

183 ere, we investigated the prognostic value of tumor-infiltrating lymphocytes (TIL) expressing CD3, Fox

184 results in the profound enhancement of CD4+ tumor-infiltrating lymphocytes (TIL) expressing FoxP3, I

185 Recent studies have found that tumor-infiltrating lymphocytes (TIL) expressing PD-1 can

186 In this study, we characterized murine tumor-infiltrating lymphocytes (TIL) for activation stat

187 equencing-based approach to demonstrate that tumor-infiltrating lymphocytes (TIL) from a patient with

188 The expansion of autologous tumor cells and tumor-infiltrating lymphocytes (TIL) from fine needle as

189 Using flow cytometry, we evaluated tumor-infiltrating lymphocytes (TIL) from patients under

190 ic changes in the tumor microenvironment and tumor-infiltrating lymphocytes (TIL) in a B-RafV600E/Pte

191 ce of adding TBI to the adoptive transfer of tumor-infiltrating lymphocytes (TIL) in a randomized fas

192 Here, we show that P2X7 activity in tumor-infiltrating lymphocytes (TIL) induces cellular se

193 The presence of tumor-infiltrating lymphocytes (TIL) is a favorable prog

194 sment of spatial relations between tumor and tumor-infiltrating lymphocytes (TIL) is increasingly imp

195 Tumor-infiltrating lymphocytes (TIL) isolated from melan

196 CD8(+) tumor-infiltrating lymphocytes (TIL) lack in vivo and in

197 ss I-restricted CD4(+) T cells obtained from tumor-infiltrating lymphocytes (TIL) of a metastatic mel

198 Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) results in complete

199 colorectal cancers have a higher density of tumor-infiltrating lymphocytes (TIL) than other colorect

200 tumor, but it has been difficult to identify tumor-infiltrating lymphocytes (TIL) that show in vitro

201 Tumor-infiltrating lymphocytes (TIL) were evident after,

202 sms of self-tolerance often result in CD8(+) tumor-infiltrating lymphocytes (TIL) with a hypofunction

203 icularly the adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL), is a very promisin

204 agent DAC led to increased CD4(+) and CD8(+) tumor-infiltrating lymphocytes (TIL), PD1 expression, an

205 d minimal toxicity in ex vivo-expanded human tumor-infiltrating lymphocytes (TIL), proliferating TILs

206 ions and correspondingly expanded autologous tumor-infiltrating lymphocytes (TIL), we show how MHC cl

207 s and with an augmented population of CD8(+) tumor-infiltrating lymphocytes (TIL).

208 mononuclear cells (PBMC), ascitic fluid, and tumor-infiltrating lymphocytes (TIL).

209 ollowing the adoptive transfer of autologous tumor-infiltrating lymphocytes (TIL).

210 ltration, cytolytic activity, and abundance (tumor infiltrating lymphocyte, TIL, burden).

211 he association of HHLA2 with the presence of tumor infiltrating lymphocytes (TILs) and five-year-even

212 stimulatory microenvironment harboring more tumor infiltrating lymphocytes (TILs) and up-regulation

213 Assessment of tumor infiltrating lymphocytes (TILs) as a prognostic va

214 Tumor infiltrating lymphocytes (TILs) have been associat

215 (RT) on the basis of the presence of stromal tumor infiltrating lymphocytes (TILs) have not been stud

216 s I-restricted CD4+ T cell isolated from the tumor infiltrating lymphocytes (TILs) of a patient with

217 dynamics of the effector response of CD8(+) tumor-infiltrating lymphocytes (TILs) after checkpoint b

218 antigen-specific, activated effector CD8(+) tumor-infiltrating lymphocytes (TILs) after interaction

219 ha- and interleukin (IL)-17-producing CD4(+) tumor-infiltrating lymphocytes (TILs) and aggressive dis

220 autoimmune diseases, their prevalence among tumor-infiltrating lymphocytes (TILs) and function in hu

221 Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) and high-dose inte

222 tive (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) and immunologicall

223 Evaluation of tumor-infiltrating lymphocytes (TILs) and PD-1 and PD-L1

224 xamined the role of CD226 in the function of tumor-infiltrating lymphocytes (TILs) and resistance to

225 ation and single-cell RNA profiles of CD8(+) tumor-infiltrating lymphocytes (TILs) and used genetic p

226 Tumor-infiltrating lymphocytes (TILs) are an important h

227 Recent studies suggest that tumor-infiltrating lymphocytes (TILs) are associated wit

228 Accumulating evidence indicates that tumor-infiltrating lymphocytes (TILs) are associated wit

229 Tumor-infiltrating lymphocytes (TILs) are considered a m

230 It is well known that CD8(+) tumor-infiltrating lymphocytes (TILs) are correlated wit

231 Tumor-infiltrating lymphocytes (TILs) are important prog

232 umors; however, the antigen specificities of tumor-infiltrating lymphocytes (TILs) are not well under

233 Adoptive cell transfer of tumor-infiltrating lymphocytes (TILs) can mediate cancer

234 rapy (ACT) using ex vivo-expanded autologous tumor-infiltrating lymphocytes (TILs) can mediate comple

235 Adoptive transfer of tumor-infiltrating lymphocytes (TILs) can mediate regres

236 sis survivors had a reduced frequency of CD8 tumor-infiltrating lymphocytes (TILs) concomitant with a

237 tive immunotherapy with autologous antitumor tumor-infiltrating lymphocytes (TILs) following nonmyelo

238 Long-term follow-up of patients receiving tumor-infiltrating lymphocytes (TILs) for metastatic mel

239 c Abs enhances the expansion and function of tumor-infiltrating lymphocytes (TILs) for treating cance

240 immunologic screening, we demonstrated that tumor-infiltrating lymphocytes (TILs) from 9 out of 10 p

241 tified a unique ILC population that inhibits tumor-infiltrating lymphocytes (TILs) from high-grade se

242 ific (TA-specific) CD8(+) T cells and CD8(+) tumor-infiltrating lymphocytes (TILs) from patients with

243 ion of ex vivo cultured, naturally occurring tumor-infiltrating lymphocytes (TILs) has been shown to

244 lls (NK), T-cells, dendritic cells (DC), and tumor-infiltrating lymphocytes (TILs) have been document

245 uced immunity, the phenotype and function of tumor-infiltrating lymphocytes (TILs) in 9Lneo and 9LmIL

246 Tregs represented a large proportion of the tumor-infiltrating lymphocytes (TILs) in claudin-low tum

247 at have investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage tri

248 The phenotype and cell cycle status of tumor-infiltrating lymphocytes (TILs) in HCC were analyz

249 lobulin mucin (Tim) 3 is expressed on CD8(+) tumor-infiltrating lymphocytes (TILs) in mice bearing so

250 o received adoptively transferred autologous tumor-infiltrating lymphocytes (TILs) in phase 2 clinica

251 the role of different subsets of regulatory tumor-infiltrating lymphocytes (TILs) in the immunopatho

252 Although the presence of tumor-infiltrating lymphocytes (TILs) indicates an endog

253 Importance: The presence of tumor-infiltrating lymphocytes (TILs) is a favorable pro

254 The presence of tumor-infiltrating lymphocytes (TILs) is associated with

255 flammation in which the effector function of tumor-infiltrating lymphocytes (TILs) is severely impair

256 We determined how CD8(+) melanoma tumor-infiltrating lymphocytes (TILs) isolated from two

257 tumor-specific CD4(+) Treg cell clones from tumor-infiltrating lymphocytes (TILs) of cancer patients

258 c CD4(+) Treg cell clones generated from the tumor-infiltrating lymphocytes (TILs) of cancer patients

259 n of T cell clones by limiting dilution from tumor-infiltrating lymphocytes (TILs) permitted function

260 Tumor-infiltrating lymphocytes (TILs) possessed higher V

261 studies suggest more favorable survival with tumor-infiltrating lymphocytes (TILs) present in primary

262 However, the evaluation of tumor-infiltrating lymphocytes (TILs) relies on histopat

263 Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) represents an effe

264 ession and chromatin accessibility in CD8(+) tumor-infiltrating lymphocytes (TILs) that recognize a m

265 s by reactivating a population of endogenous tumor-infiltrating lymphocytes (TILs) that recognize can

266 In a recent report,, the presence of CD3+ tumor-infiltrating lymphocytes (TILs) was found to corre

267 FS), multifunctionality of CD8 + splenic and tumor-infiltrating lymphocytes (TILs) was impaired and a

268 Tumor-infiltrating lymphocytes (TILs) were scored in hem

269 Percentage of tumor cells and tumor-infiltrating lymphocytes (TILs) with PD-L1 express

270 The distribution of tumor-infiltrating lymphocytes (TILs) within the tumor m

271 ent survival, an immune response linked with tumor-infiltrating lymphocytes (TILs), and a repressed C

272 infiltrating immune cells (IC), abundance of tumor-infiltrating lymphocytes (TILs), and expression of

273 transfer from melanoma to T cells, including tumor-infiltrating lymphocytes (TILs), and subsequently

274 ed from peripheral blood lymphocytes (PBLs), tumor-infiltrating lymphocytes (TILs), and tumor-associa

275 mphoid progenitor cells and cytotoxic CD8(+) tumor-infiltrating lymphocytes (TILs), leading to a majo

276 CRC for the presence of functionally active tumor-infiltrating lymphocytes (TILs), the tumor specifi

277 of TCRbeta(+) CD8(+) IL-17(+) T cells among tumor-infiltrating lymphocytes (TILs).

278 s associated with the absence or presence of tumor-infiltrating lymphocytes (TILs).

279 signaling from naive to dysfunctional CD8(+) tumor-infiltrating lymphocytes (TILs).

280 ells share core residency gene programs with tumor-infiltrating lymphocytes (TILs).

281 a specific subpopulation of exhausted CD8(+) tumor-infiltrating lymphocytes (TILs).

282 ive T cell therapy (ACT) of ex vivo expanded tumor-infiltrating lymphocytes (TILs).

283 modulating inhibitory receptor expression on tumor-infiltrating lymphocytes (TILs); however, the unde

284 Intraepithelial/stromal tumor-infiltrating lymphocytes (TILs; CD3(+)/CD4(+)/CD8(

285 -eosin and immunohistochemical stainings for tumor-infiltrating lymphocytes, tissue-based hypoxia, an

286 Singer et al. characterize dysfunctional tumor infiltrating lymphocytes to reveal a role for zinc

287 METHODSWe recently developed a process using tumor-infiltrating lymphocytes to identify the specific

288 ssel endothelial cells, and 2) acting on the tumor-infiltrating lymphocytes to indirectly alter endot

289 le MEK inhibition can promote recruitment of tumor-infiltrating lymphocytes to the tumor, here we sho

290 The number of tumor-infiltrating lymphocytes was also reduced in LKB1-

291 ly, traditional histologic identification of tumor-infiltrating lymphocytes was not a significant ind

292 The upregulation of IL-17-secreting CD4(+) tumor-infiltrating lymphocytes was substantiated at the

293 Activated and proliferating tumor-infiltrating lymphocytes were evident in these mic

294 To characterize the putative T-pro cells, tumor-infiltrating lymphocytes were isolated from normal

295 Finally, tumor-reactive in vitro expanded tumor infiltrating lymphocytes, which are used clinicall

296 The TCR alpha- and beta-chain genes from a tumor-infiltrating lymphocyte, which recognized the tyro

297 h model, GSK-3i inhibited PD-1 expression on tumor-infiltrating lymphocytes, while increasing Tbx21 (

298 The growth of large numbers of tumor-infiltrating lymphocytes with in vitro anti-cancer

299 In addition, tumor-infiltrating lymphocytes with reactivity against n

300 lls and enhancement of antitumor activity in tumor-infiltrating lymphocytes without disrupting immune